- Home
- NTIP vs LSTA Comparison
NTIP vs LSTA Comparison
Compare NTIP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | LSTA |
|---|---|---|
| Founded | 1990 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Misc Health and Biotechnology Services |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 28.9M |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NTIP | LSTA |
|---|---|---|
| Price | $1.62 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 49.1K | ★ 65.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | 15.38 | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 50.00 | ★ 56.90 |
| 52 Week Low | $1.24 | $1.81 |
| 52 Week High | $1.75 | $5.07 |
Technical Indicators
Market Signals| Indicator | NTIP | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 69.28 | 19.52 |
| Support Level | $1.39 | N/A |
| Resistance Level | $1.67 | $2.19 |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 95.83 | 1.40 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.